metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population
versus docetaxel
	nivolumab alone
	CheckMate 078, 2019 J Thorac Oncol 2019; 14:867-875 Lung Cancer 2020 Nov 24;152:7-14. Lung Cancer 2021 Dec 27;165:71-81. NCT02613507	RCT	mNSCLC - L2 - all population	nivolumab	docetaxel	Patients with stage IIIB or IV or recurrent squamous or nonsquamous NSCLC progressing during or after one previous platinumbased doublet chemotherapy regimen. (predominantly Chinese patient)	338 / 166	some concern	conclusif	demonstrated 32 % decrease in deaths (OS) (PE) demonstrated 23 % decrease in progression or deaths (PFS) (PE) suggested 25 % decrease in deaths (OS) (extension) suggested 21 % decrease in PFS (extension) more...
non squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) non squamous cell - mNSCLC - L2 non squamous - mNSCLC - L2 - all population
versus docetaxel
	nivolumab alone
	CheckMate 057, 2015 N Engl J Med 2015;373:1627-39 Eur. J. Cancer 2018; 102:23-30 J. Clin. Oncol. 2017; 35:3924-3933 J Clin Oncol 2021 Mar 1;39(7):723-733. NCT01673867	RCT	non squamous - mNSCLC - L2 - all population	nivolumab	docetaxel	Patients with advanced (stage IIIb or IV or recurrent) nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy	292 / 290	some concern	conclusif	demonstrated 27 % decrease in deaths (OS) (PE) demonstrated 70 % increase in objective responses (ORR) (PE)
squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) squamous cell - mNSCLC - L2 squamous - mNSCLC - L2 - all population
versus docetaxel
	nivolumab alone
	CheckMate 017, 2015 J Thorac Oncol 2018; 13:194-204 J. Clin. Oncol. 2017; 35:3924-3933 N. Engl. J. Med. 2015; 373:123-35 J Clin Oncol 2021 Mar 1;39(7):723-733. NCT01642004	RCT	squamous - mNSCLC - L2 - all population	Nivolumab	Docetaxel	Patients with stage IIIB or IV squamous-cell NSCLC who had disease recurrence after only one prior platinum-containing regimen	135 / 137	some concern	conclusif	demonstrated 41 % decrease in deaths (OS) (PE) demonstrated 38 % decrease in progression or deaths (PFS) (PE) suggested 69 % decrease in deaths (OS) (extension) suggested 52 % decrease in PFS (extension) more...